



<sup>1</sup> **Severe Immunocompromised:** Clinical judgement remains important to determine if these patients should be considered as severely immune compromised for the purpose of determining their communicability period. Refer [Definition & management of Immunocompromised Patients](#)

**PLEASE NOTE:** Patients with mild immune compromising conditions and/or factors such as **advanced age, diabetes mellitus or end-stage renal disease** are treated in the same manner as those **without** immune compromising conditions and/or factors for the purpose of discontinuing additional precautions.

<sup>2</sup> **Symptom improvement:**

- Patient has returned to baseline respiratory status with respect to oxygen requirements and/or pre-existing cough or other respiratory issues **and**
- Patient has returned to baseline gastrointestinal status (bowel movements, no emesis) **and**
- Patient has been afebrile for  $\geq 24$ hrs without the use of fever reducing medications

**PLEASE NOTE:**

This does not necessarily apply to pre-existing or chronic respiratory symptoms caused by another health condition. Coughing may persist for several weeks and does not mean the patient is infectious and must remain on additional precautions, provided that the patient is afebrile and other symptoms have improved.

<sup>3</sup>**Test Based Strategy** is considered in limited number of scenarios **only** (severe immunocompromised, etc.). Twenty days have passed since onset of symptoms (consider longer period based on consultation with MRP) AND at least 24 hours have passed since last fever without the use of fever-reducing medication AND symptoms (respiratory, gastrointestinal and systemic) have improved. For assistance with test-based approach please consult IPAC or Medical Microbiologist on-call.

Effective Date	December 2023		
Last Reviewed	October 2025		
Partners Reviewed	Access & Flow, ED Network, Workplace Health & Safety		
Approved By	IPAC		
Owner	Infection Prevention and Control		
Revision History	Date	Section	Revision
	October 2025		<ul style="list-style-type: none"> <li>• Updated symptoms to match symptoms described in syndromic screening toolkit.</li> <li>• Included link to droplet &amp; contact precautions</li> <li>• Included update COVID-19 harmonization recommendations of no test based strategy.</li> <li>• Removed definition of moderate immunocompromised.</li> <li>• Removed immunosuppressed definition and substituted for link to IPAC document.</li> </ul>